
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics Inc. demonstrates a robust upward trajectory in its prescription volume, evidenced by a 41% sequential increase in written prescriptions from September to October in 4Q25, surpassing the entire third-quarter volume within the initial weeks of the fourth quarter. The expansion of the sales force from 50 to 64 territory managers aims to enhance clinician coverage from approximately 8,000 to 10,000, thereby positioning the company for potential share gains in the expansive impetigo market. As treatment rates are expected to rise alongside improved prescriber adoption and positive feedback from key opinion leaders, Pelthos's existing commercial model is poised for significant revenue contributions from its current and future product offerings.
Bears say
Pelthos Therapeutics Inc. faces significant challenges that could adversely affect its financial performance and stock outlook. The company risks lower-than-expected sales and margins if it fails to secure adequate reimbursement or formulary placement, and slow adoption by healthcare professionals could further hinder revenue growth. Additionally, the potential failure of clinical-stage products to deliver significant trial results or gain regulatory approval poses a substantial threat to the overall value of Pelthos's product candidates, while competitive pressures in the market may limit their ability to capture projected revenues.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares